

LOMUSTINE

INDICATION (ICD10) C71, C72

1. High and low grade gliomas (relapse following first line treatment). PS 0, 1, 2

REGIMEN

Day 1 LOMUSTINE (CCNU) 100mg/m² (maximum 200mg) orally single dose only

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 42 days for up to 6 cycles

ADMINISTRATION

Available as 40mg capsules
Take at night on an empty stomach

ANTI-EMETICS

Moderate risk day 1 (take before lomustine dose)

Patients may already be taking dexamethasone for raised intracranial pressure

CONCURRENT MEDICATION REQUIRED

| | · |
|-----------|--|
| Lomustine | Lorazepam 1mg single dose may be helpful |

EXTRAVASATION AND TYPE OF LINE / FILTERS

Not applicable

INVESTIGATIONS

Blood results required before SACT administration FBC, U&E and LFTs every cycle Neutrophils x 10⁹/L ≥1.5 Platelets x 10⁹/L ≥100 Serum creatinine every cycle Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

| 1 (1 | |
|-----------|------------------|
| Lomustine | Myelosuppression |
| Lomusimo | INITION |

DOSE MODIFICATIONS

Haematological

Lomustine

If neutrophils $<1.5x10^9/L$ and platelets $<100x10^9/L$, delay 1 week or until count recovered then restart at 75% dose, then at 50% dose with further myelosuppression, dose can be reduced further to 25% dose.

Renal impairment

Lomustine

| Lomustine | | | | |
|------------------|-----------------|--|--|--|
| CrCl >60ml/min | give 100% | | | |
| CrCl 45-60ml/min | give 75% | | | |
| CrCl 30-45ml/min | give 50% | | | |
| CrCl <30ml/min | Not recommended | | | |

| Lomustine | CNS CAG approval | Page 1 of 2 | Approved: December 2021 | Version |
|-----------|------------------|-------------|-------------------------|---------|
| | | | Review: December 2023 | 5.0 |



REFERENCES

- 1. Thomas D et al. J Clin Oncol; 19: 509-518
- 2. Cairncross et al. 2013 RTOG 9402 trial
- 3. Taal et al. 2014 BELOB study